Phase 3 Alogliptin Pediatric Study
Diabetes Mellitus - Type 2
What is the purpose of this trial?
This study will evaluate the efficacy and safety of alogliptin 25 mg once daily (QD) compared to placebo when administered as monotherapy, or when added onto a background of metformin alone, insulin alone, or a combination of metformin and insulin in pediatric participants 10 to 17 years of age with type 2 diabetes mellitus (T2DM).
- Ages10 - 17 years
- Trial withTakeda Pharmaceuticals, America, Inc.
- Start Date08/08/2018
- End Date06/10/2021
- Last Updated08/14/2018
- Study HIC#2000022953